Fig. 2.

naAbs to type I IFNs were detected by the neutralization assay in 622 patients with COVID-19 at a cytokine concentration of 10 ng/mL. A Dot plot of the neutralization assay stimulated by 10 ng/mL of type I IFNs. The samples showing less than 15% of luciferase activity were defined as having neutralization activity. The prevalence of naAbs was high in patients with critical COVID-19. B Neutralizing activity against type I IFNs was compared between IFN-α2 and IFN-ω stimulated by 10 ng/mL. All patients having neutralizing activity against IFN-ω had neutralizing activity against IFN-α2. C The odds ratio (OR) associated with COVID-19 aggravation among patients in critical disease compared to mild/moderate disease